ReviewCancers2024
Clinical Theranostics in Recurrent Gliomas: A Review.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Post-therapy imaging of adult brain tumours: patterns, pitfalls, and practical framework.Insights into imaging · 2026Article
- Nanotheranostics armed with folate: an integrated approach for precision targeting of glioblastoma.Medical oncology (Northwood, London, England) · 2026Review
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Complement system-related gene signatures implicated in the recurrence of glioma.Translational cancer research · 2026Article
- Advances in glioblastoma: Is there light at the end of the tunnel?The Indian journal of medical research · 2026Article
- Brain Cancer: Molecular Alterations and Emerging Trends in Neuropharmacology.International journal of molecular sciences · 2026Review
- Article
- Magnetically Controlled Nanocarriers for Site-Specific Drug Delivery and Theranostics in Cancer Precision Medicine.Molecular imaging and biology · 2026Review
- Development and Validation of an Early Recurrence Prediction Model for High-Grade Glioma Integrating Temporalis Muscle and Tumor Features: Exploring the Prognostic Value of Temporalis Muscle.Journal of imaging informatics in medicine · 2026Article
- Evaluating the Antitumor Potential of Cannabichromene, Cannabigerol, and Related Compounds fromInternational journal of molecular sciences · 2025Article
- Expanding the Scope of Interventional Oncology: Locoregional Therapies in Extrahepatic Malignancies.Cancers · 2025Review
- Multi-Modality Fusion and Tumor Sub-Component Relationship Ensemble Network for Brain Tumor Segmentation.Bioengineering (Basel, Switzerland) · 2025Article
- Nuclear Medicine Imaging Techniques in Glioblastomas.Neurochemical research · 2024Review
- Application of preoperative advanced diffusion magnetic resonance imaging in evaluating the postoperative recurrence of lower grade gliomas.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Epidemiology and risk factors for adult gliomas died by respiratory diseases during the COVID-19 pandemic: a population-based study.Neurosurgical review · 2024Article
- Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas represent the most commonly occurring tumors in the central nervous system and account for approximately 80% of all malignant primary brain tumors. With a high malignancy and recurrence risk, the prognosis of high-grade gliomas is poor, with a mean survival time of 12-18 months. While contrast-enhanced MRI serves as the standard diagnostic imaging modality for gliomas, it faces limitations in the evaluation of recurrent gliomas, failing to distinguish between treatment-related changes and tumor progression, and offers no direct therapeutic options. Recent advances in imaging modalities have attempted to address some of these limitations, including positron emission tomography (PET), which has demonstrated success in delineating tumor margins and guiding the treatment of recurrent gliomas. Additionally, with the advent of theranostics in nuclear medicine, PET tracers, when combined with therapeutic agents, have also evolved beyond a purely diagnostic modality, serving both diagnostic and therapeutic roles. This review will discuss the growing involvement of theranostics in diagnosing and treating recurrent gliomas and address the associated impact on quality of life and functional recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.